https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-17 / Front Oncol 2015;5:98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-17 / Front Oncol 2015;5:982015-06-17 00:00:002021-11-15 13:27:21Brain Tumor Immunotherapy: What have We Learned so Far?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-322015-06-13 00:00:002021-11-15 13:28:49Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr 2036)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr 2036)2015-06-01 12:02:252019-07-17 12:02:49Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-29 / J. Immunol. 2015 Jul;195(1):367-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-29 / J. Immunol. 2015 Jul;195(1):367-762015-05-29 00:00:002019-02-15 08:47:19Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-02-20 / Cancer Res. 2015 Apr;75(8):1760-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-02-20 / Cancer Res. 2015 Apr;75(8):1760-92015-02-20 00:00:002019-02-15 09:00:11Hyperthermia Sensitizes Glioma Stem-like Cells to Radiation by Inhibiting AKT Signaling
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-15 / J Cancer 2015;6(3):203-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-15 / J Cancer 2015;6(3):203-172015-01-15 00:00:002021-11-15 13:29:28Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-01 / Drugs Future 2015;40(11):739-749
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-01 / Drugs Future 2015;40(11):739-7492015-01-01 00:00:002019-02-15 09:00:22EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-01-01 / Cancer Treat. Res. 2015;163:143-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-01-01 / Cancer Treat. Res. 2015;163:143-582015-01-01 00:00:002019-02-15 08:46:19Immunotherapy for malignant gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-11-01 / EMBO Mol Med 2014 Nov;6(11):1359-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-11-01 / EMBO Mol Med 2014 Nov;6(11):1359-702014-11-01 00:00:002019-02-15 08:47:43Emerging treatment strategies for glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-11-01 / Curr Opin Oncol 2014 Nov;26(6):608-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-11-01 / Curr Opin Oncol 2014 Nov;26(6):608-142014-11-01 00:00:002019-02-15 08:46:20Perspectives for immunotherapy in glioblastoma treatment
